| Developments in Pharmaceutical and Biotech Patent Law 2012 TOC |
|
|
| Chapter 1: Therasense and the State of Inequitable Conduct Jurisprudence |
Janet B. Linn ~ Eckert Seamans Cherin & Mellot, LLC
Janet T. Munn ~ Rasco Klock
|
|
| Chapter 2: Opinion, Therasense, Inc., et al., v. Becton, Dickinson and Company, et al., 2008-1511, -1512, -1513, -1514, -1595, (RRR, FED. CIR., May 25, 2011) |
Janet B. Linn ~ Eckert Seamans Cherin & Mellot, LLC
Janet T. Munn ~ Rasco Klock
|
|
| Chapter 3: America Invents Act: An Overview |
Daniel L. Reisner ~ Kaye Scholer LLP
|
|
| Chapter 4: Leahy-Smith America Invents Act, Public Law 112-29--Sept. 16, 2011 |
Daniel L. Reisner ~ Kaye Scholer LLP
|
|
| Chapter 5: America Invents Act, Legislative History (Extract), 112th Congress, 1st Session, House of Representatives, Rept. 112-98 Part 1 |
Daniel L. Reisner ~ Kaye Scholer LLP
|
|
| Chapter 6: AIA and Therasense: A Corporate Practitioner Perspective |
Dean Olson ~ Senior Corporate Counsel, Pfizer Inc.
Ian J.S. Lodovice ~ Corporate Counsel - Intellectual Property, Pfizer Inc.
|
|
| Chapter 7: Section 101 Post-Bilski: Recent Case Law Developments Relating to the Scope of Patentable Subject Matter in Pharmaceutical and Biotech Cases |
David K. Barr ~ Kaye Scholer LLP
|
|
| Chapter 8: Utility and Patentable Subject Matter Requirements, Excerpted from Pharmaceutical and Biotech Patent Law, Chapter 3, (Item #15140, pp. 3-1 - 3-21) Kaye Scholer LLP (PLI 2007; Supp. 2011) |
|
|
| Chapter 9: The Cutting Edge: Reviewing Major Decisions in the Past Year and Pending Supreme Court and Federal Circuit En Banc Petitions |
Benjamin C. Hsing ~ Kaye Scholer LLP
|
|
| Chapter 10: Local Civil and Criminal Rules of the United States District Court for the District of New Jersey (With Revisions As of November 1, 2011) |
Liza M. Walsh ~ Connell Foley LLP
|
|
| Chapter 11: Index to Developments in Pharmaceutical and Biotech Patent Law 2012 |
|
|